Connecta Therapeutics raises €1.7 M to develop new treatment for fragile X syndrome

by Parc Científic de Barcelona

Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...

Read more

La inmunoterapia abre la puerta a un tratamiento estándar de primera línea para las pacientes con un subtipo de cáncer de endometrio avanzado

by Vall d’Hebron

Los resultados del estudio GARNET, liderado por Vall d’Hebron, abren la puerta a una nueva terapia para pacientes con cáncer de endometrio avanzado con deficiencia en el sistema de reparación de e...

Read more

Optogenetic therapy to restore advanced vision loss in retinal dystrophies

by DBGen Ocular Genomics

​ Gene therapies currently under study for retinal dystrophies are administered when viable photoreceptor able to be rescued at the functional level still remain. Most therapies are gene-specific...

Read more

FreeOx acquires the patent for the drug Ox-01 in the US for ischaemic stroke

by CataloniaBio

FreeOx Biotech, a CataloniaBio & HealthTech member, has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use o...

Read more

Metoprolol: an old drug with unique cardioprotective properties

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

CNIC scientists have defined the unique ability if metoprolol to protect the heart during a heart attack

Read more

Immuneel Therapeutics, Hospital Clínic de Barcelona & IDIBAPS Announce a Strategic collaboration & a License Agreement

by Fundació Clínic per a la Recerca Biomèdica

Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Hospital Clínic de Barcelona (HCB) and Institut d’...

Read more

ORYZON publishes paper in Journal of Clinical Oncology demonstrating relevance of iadademstat in leukemia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the p...

Read more

American Hospital of Paris and OncoDNA Partner to Advance Breast Cancer Patients Management

by OncoDNA

American Hospital of Paris and OncoDNA announced a new joint initiative that is intended to advance the use of precision medicine in routine clinical practice for patients with metastatic breast cance...

Read more

Una treintena de ensayos clínicos con células madre contra la Covid-19, seis de ellos en España

by Secuvita

El mundo trabaja a contrarreloj para conseguir un tratamiento contra la Covid-19. Y las células madre son una de las alternativas en las que los investigadores están poniendo el foco. Actualmente es...

Read more

El gran ensayo de la OMS no encuentra tratamientos efectivos para pacientes hospitalizados por la covid-19

by Agencia Sinc
  • 4 years ago

El estudio Solidarity, coordinado por la Organización Mundial de la Salud en más de 30 países, indica que las terapias con remdesivir, hidroxicloroquina, lopinavir/ritonavir e interferón no han te...

Read more

SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2

by Som Biotech

SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020.

Read more

ORYZON holds its 4th annual Solidarity Day

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, celebrated yest...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream